Medicskin Holdings Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Medicskin Holdings te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Healthcare winstgroei	18.9%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

We Think Some Shareholders May Hesitate To Increase Medicskin Holdings Limited's (HKG:8307) CEO Compensation

Sep 15

Here's Why Shareholders May Want To Be Cautious With Increasing Medicskin Holdings Limited's (HKG:8307) CEO Pay Packet

Sep 16

Here's Why We Think Medicskin Holdings (HKG:8307) Is Well Worth Watching

Jul 18

Investor Optimism Abounds Medicskin Holdings Limited (HKG:8307) But Growth Is Lacking

Jun 11

A Look At The Fair Value Of Medicskin Holdings Limited (HKG:8307)

Feb 25

Shareholders Will Probably Hold Off On Increasing Medicskin Holdings Limited's (HKG:8307) CEO Compensation For The Time Being

Sep 15

Can Mixed Fundamentals Have A Negative Impact on Medicskin Holdings Limited (HKG:8307) Current Share Price Momentum?

Feb 11

Our Take On Medicskin Holdings' (HKG:8307) CEO Salary

Dec 16

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Medicskin Holdings onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

SEHK:8307 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (HKD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2024	48	-3	8	9	N/A
6/30/2024	48	-4	N/A	N/A	N/A
3/31/2024	50	-3	9	11	N/A
12/31/2023	51	-3	N/A	N/A	N/A
9/30/2023	51	-2	3	5	N/A
6/30/2023	49	-3	N/A	N/A	N/A
3/31/2023	46	-4	1	3	N/A
12/31/2022	41	-2	N/A	N/A	N/A
9/30/2022	43	-1	2	3	N/A
6/30/2022	46	2	N/A	N/A	N/A
3/31/2022	49	4	2	4	N/A
12/31/2021	49	1	N/A	N/A	N/A
9/30/2021	47	1	3	5	N/A
6/30/2021	45	2	N/A	N/A	N/A
3/31/2021	42	1	7	9	N/A
12/31/2020	42	1	N/A	N/A	N/A
9/30/2020	43	-1	10	12	N/A
6/30/2020	45	-2	N/A	N/A	N/A
3/31/2020	48	-3	13	15	N/A
12/31/2019	51	-3	N/A	N/A	N/A
9/30/2019	52	-3	9	12	N/A
6/30/2019	52	-5	N/A	N/A	N/A
3/31/2019	51	-5	0	4	N/A
12/31/2018	52	-2	N/A	N/A	N/A
9/30/2018	53	-1	-1	2	N/A
6/30/2018	55	1	N/A	N/A	N/A
3/31/2018	58	3	N/A	6	N/A
12/31/2017	61	3	N/A	N/A	N/A
9/30/2017	63	3	N/A	23	N/A
6/30/2017	63	3	N/A	N/A	N/A
3/31/2017	62	3	N/A	16	N/A
12/31/2016	60	3	N/A	N/A	N/A
9/30/2016	59	2	N/A	0	N/A
6/30/2016	58	2	N/A	N/A	N/A
3/31/2016	60	2	N/A	2	N/A
12/31/2015	62	4	N/A	N/A	N/A
9/30/2015	64	3	N/A	1	N/A
6/30/2015	65	3	N/A	N/A	N/A
3/31/2015	67	3	N/A	6	N/A
12/31/2014	68	2	N/A	N/A	N/A
3/31/2014	65	14	N/A	23	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van 8307 boven de spaarquote ( 2.3% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van 8307 naar verwachting sneller zal groeien dan de markt Hong Kong

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van 8307 naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van 8307 naar verwachting sneller zal groeien dan de markt Hong Kong.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van 8307 naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 8307 naar verwachting over 3 jaar hoog zal zijn

Medicskin Holdings Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Medicskin Holdings Limited Provides Unaudited Consolidated Earnings Guidance for Six Months Ended 30 September 2022

Medicskin Holdings Limited Provides Consolidated Earnings Guidance for the Three Months Ended June 30, 2022

Recent updates

New major risk - Revenue and earnings growth

Medicskin Holdings Limited to Report First Half, 2025 Results on Nov 21, 2024

New major risk - Market cap size

Medicskin Holdings Limited, Annual General Meeting, Sep 06, 2024

Full year 2024 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in FY 2023)

Now 34% overvalued after recent price rise

New minor risk - Financial data availability

Medicskin Holdings Limited to Report Fiscal Year 2024 Results on Jun 19, 2024

New minor risk - Share price stability

Now 20% overvalued after recent price rise

Now 23% undervalued after recent price drop

Second quarter 2024 earnings released: HK$0.004 loss per share (vs HK$0.006 loss in 2Q 2023)

New major risk - Market cap size

Medicskin Holdings Limited to Report Q2, 2024 Results on Nov 13, 2023

We Think Some Shareholders May Hesitate To Increase Medicskin Holdings Limited's (HKG:8307) CEO Compensation

Medicskin Holdings Limited Announces Appointment of Lui Sze On as Independent Non-Executive Director and Member of the Audit Committee, Remuneration Committee and Nomination Committee of the Board with Effect from September 6, 2023

New minor risk - Financial position

First quarter 2024 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 1Q 2023)

First quarter 2024 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 1Q 2023)

Medicskin Holdings Limited to Report Q1, 2024 Results on Aug 14, 2023

Medicskin Holdings Limited, Annual General Meeting, Sep 01, 2023

New minor risk - Share price stability

Full year 2023 earnings released: HK$0.007 loss per share (vs HK$0.01 profit in FY 2022)

Medicskin Holdings Limited Announces Resignation of Fu Frank Tsun Yin as Independent Non-Executive Director and A Member of the Audit Committee, Remuneration Committee and Nomination Committee

Medicskin Holdings Limited to Report Fiscal Year 2023 Results on Jun 21, 2023

Medicskin Holdings Limited Appoints Fu Frank Tsun Yin as an Independent Non-Executive Director and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee of the Board with Effect from 14 February 2023

Third quarter 2023 earnings released: EPS: HK$0 (vs HK$0.004 in 3Q 2022)

Medicskin Holdings Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: HK$0.006 loss per share (vs HK$0.001 profit in 2Q 2022)

Medicskin Holdings Limited Announces Resignation of Lee Ka Lun as Independent Non-Executive Director and Member of the Audit Committee, Remuneration Committee and Nomination Committee

Less than half of directors are independent

Medicskin Holdings Limited Provides Unaudited Consolidated Earnings Guidance for Six Months Ended 30 September 2022

Medicskin Holdings Limited to Report First Half, 2023 Results on Nov 14, 2022

Here's Why Shareholders May Want To Be Cautious With Increasing Medicskin Holdings Limited's (HKG:8307) CEO Pay Packet

First quarter 2023 earnings released: HK$0.002 loss per share (vs HK$0.004 profit in 1Q 2022)

Medicskin Holdings Limited Provides Consolidated Earnings Guidance for the Three Months Ended June 30, 2022

Here's Why We Think Medicskin Holdings (HKG:8307) Is Well Worth Watching

Medicskin Holdings Limited, Annual General Meeting, Sep 23, 2022

Full year 2022 earnings released

Medicskin Holdings Limited, Annual General Meeting, Sep 23, 2022

Investor Optimism Abounds Medicskin Holdings Limited (HKG:8307) But Growth Is Lacking

Medicskin Holdings Limited to Report Fiscal Year 2022 Results on Jun 20, 2022

Less than half of directors are independent

Now 20% undervalued

A Look At The Fair Value Of Medicskin Holdings Limited (HKG:8307)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS HK$0.001 (vs HK$0.002 in 2Q 2021)

Shareholders Will Probably Hold Off On Increasing Medicskin Holdings Limited's (HKG:8307) CEO Compensation For The Time Being

First quarter 2022 earnings released: EPS HK$0.004 (vs HK$0.002 in 1Q 2021)

Inaugural dividend of HK$0.025 per share

Full year 2021 earnings released: EPS HK$0.002 (vs HK$0.007 loss in FY 2020)

Medicskin Holdings Limited Announces Special Dividend for the Year Ended 31 March 2021, Payable on or around 26 July 2021

New 90-day high: HK$0.29

Can Mixed Fundamentals Have A Negative Impact on Medicskin Holdings Limited (HKG:8307) Current Share Price Momentum?

Third quarter 2021 earnings released: EPS HK$0.004 (vs HK$0.001 loss in 3Q 2020)

New 90-day high: HK$0.28

Medicskin Holdings Limited to Report Nine Months, 2021 Results on Feb 10, 2021

New 90-day high: HK$0.22

Our Take On Medicskin Holdings' (HKG:8307) CEO Salary

New 90-day high: HK$0.21

Second quarter 2021 earnings released: EPS HK$0.002

Medicskin Holdings Limited to Report First Half, 2021 Results on Nov 13, 2020

First quarter earnings released

Medicskin Holdings Limited to Report Q1, 2021 Results on Aug 14, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven